Therapeutic Tumor Macrophage Reprogramming in Breast Cancer Through a Peptide-Drug Conjugate
Anni LeplandiD, Elisa PeranzoniiD, Uku HaljasorgiD, Eliana K. AsciuttoiD, Maria Crespí‐Amer, Lorenzo ModestiiD, Kalle KilkiD, Manuel Lombardía, Gerardo AcostaiD, Míriam RoyoiD, Pärt PetersoniD, Ilaria MarigoiD, Tambet TeesaluiD, Pablo ScodelleriD
Abstract
In triple negative breast cancer (TNBC), pro-tumoral macrophages promote metastasis and suppress the immune response. To target these cells, we engineered a previously identified CD206 (mannose receptor)-binding peptide, mUNO, to enhance its affinity and proteolytic stability. The new rationally designed peptide, MACTIDE, includes a trypsin inhibitor loop, from the Sunflower Trypsin Inhibitor-I. Binding studies to recombinant CD206 revealed a 15-fold lower KD for MACTIDE compared to parental mUNO. Additionally, mass spectrometry showed a 5-fold increase in half-life in tumor lysate for MACTIDE compared to mUNO. Homing studies in TNBC-bearing mice showed that fluorescein (FAM)-MACTIDE precisely targeted CD206+ tumor-associated macrophages (TAMs) upon intravenous, intraperitoneal and even oral administration, with no significant accumulation in liver. We coupled MACTIDE to the FDA-approved drug Verteporfin, an established photosensitizer for photodynamic therapy and inhibitor of the YAP/TAZ pathway, to generate a conjugate here referred to as MACTIDE-V. In the orthotopic 4T1 TNBC mouse model, non-irradiated MACTIDE-V-treated mice unexpectedly showed a similar anti-tumoral effect and fewer signs of toxicity as irradiated MACTIDE-V-treated mice, leading to subsequent studies on the laser-independent activity of this conjugate. In vitro studies using bone-marrow derived mouse macrophages showed that MACTIDE-V excluded YAP from the nucleus, increased the phagocytic activity and upregulated several genes associated with cytotoxic anti-tumoral macrophages. In mouse models of TNBC, MACTIDE-V slowed primary tumor growth, suppressed lung metastases, increased markers of phagocytosis and antigen presentation in TAMs and monocytes, increasing the tumor infiltration of several lymphocyte subsets. We therefore propose MACTIDE-V as a useful peptide-drug conjugate to modulate macrophage function in the context of breast tumor immunotherapy.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 21
- FWCI
- 6.85
- Field percentile
- top 2%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Depletion of CD206+ Tumour Macrophages via a Peptide-Targeted Star-Shaped Polyglutamate Inhibits Tumourigenesis and Metastatic Dissemination in Breast Cancer Models
A. Lepland, A. Malfanti, … P. Scodeller·bioRxiv·Dec 29, 2021
- Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and anti-tumoral activity upon IL-10 or TGFβ stimulation
Sabrina Traxel, Florian Schmidt, … Simon Bredl·Journal for ImmunoTherapy of CancerPeer-reviewed·Oct 1, 2025
- Polypharmacological Re-programming of Tumor-associated Macrophages Restores Antitumor Immunity
N. Nishida-Aoki, T. S. Gujral·bioRxiv·Apr 10, 2021
- MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer
Alex J. Smith, Zachary Schrank, … Jeffrey M. Rosen·Cancer Immunology ResearchPeer-reviewed·Aug 17, 2026
- Activating a collaborative innate-adaptive immune response to control breast and ovarian cancer metastasis
L. Sun, T. Kees, … M. EGEBLAD·Cancer CellPeer-reviewed·Oct 1, 2021
- IGF1R-Targeted Delivery of a Bridged Nucleic Acid Oligonucleotide-Peptide Conjugate for MicroRNA 21 Inhibition in Triple-Negative Breast Cancer
Yuanyuan Jin, Vilas Desai, … Eric Wickstrom·NAR CancerPeer-reviewed·Oct 7, 2025